Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baricitinib - Eli Lilly and Company/Incyte Corporation

Next Previous
Drug Profile

Baricitinib - Eli Lilly and Company/Incyte Corporation

Alternative Names: INCB 028050; INCB 28050; LY 3009104; Olumiant

Latest Information Update: 09 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Eli Lilly and Company; Incyte Corporation; Natco Pharma
  • Class Acetonitriles; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azetidines; Eye disorder therapies; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic lupus erythematosus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia areata; Atopic dermatitis; Rheumatoid arthritis
  • Registered COVID 2019 infections
  • Phase III Diabetes mellitus; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Uveitis
  • Phase II/III Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
  • Discontinued Diabetic nephropathies; Primary biliary cirrhosis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus

Most Recent Events

  • 27 Feb 2026 Preregistration for Alopecia areata (In adolescents) in European Union (PO)
  • 27 Feb 2026 Preregistration for Alopecia areata (In adolescents) in USA (PO)
  • 27 Feb 2026 CHMP recommends approval of baricitinib for severe Alopecia areata (In adolescents) (PO) in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top